1513 Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial

Chronic venous leg ulcers cause significant morbidity in patients and the majority reoccur after resolution. The current standard of care, double layer compression, is not effective all patients. Interleukin 17A (IL17) antagonist therapy has been shown to promote healing murine models chronic wounds. This previously explored humans. Therefore, we aim undertake a phase II randomized, double-blinded, placebo-controlled pilot trial assess whether Ixekizumab, an anti-IL17A therapy, at reducing ulcer size. In addition, determine feasibility safety undertaking randomized control trial. Patients with responsive 4 weeks compression were recruited. Participant receive either Ixekizumab (80mg) or placebo injected subcutaneously every fortnight for 12 while continuing care. From 30 eligible, consented, enrolled randomized. Initially, COVID-19 risk, medical history distance from recruiting site main causes exclusion refusal participate. All participants completed 12-week treatment period. At completion, two group reduced by >40% one completely resolved their ulcer. Ulcers average size 955mm2 529mm2at baseline final review respectively (p-value 0.12). <5%.There no adverse events related intervention. clinical investigated novel showed IL17 inhibition does impede may improve wound healing. It also lack major issues using this population. Moreover, findings reinforce larger more accurately evaluate anti-inflammatory strategies